AIM Vaccine Co., ltd.

RECVAX®  patented adjuvant technology, through in situ adsorption technology, creates an "antigen bank" in the body after the product enters, steadily releasing antigens, extending the duration of antigen action, playing a role in enhancing the stimulation of the immune response, and improving immunogenicity.

This product is suitable for individuals who are susceptible to hepatitis B and are 16 years of age or older. It is especially recommended for healthcare workers engaged in medical practice and laboratory personnel who come into contact with blood.

Among domestic 20μg hepatitis B vaccines, only RECVAX® uses a 0.5mL smaller volume.

Better vaccination experience: Reduces vaccination and pain duration.

The content of adjuvants and other impurities is halved, effectively reducing the risk and severity of adverse reactions caused by residue.

Data from the vaccination of over 800 college students with 20μg Hansenula Polymorpha hepatitis B vaccine shows a seroconversion rate of 99.41% and an antibody titer of 1511.88 mIU/mL.

Immunization Routine and Dosage

(1) Administered via intramuscular injection into the deltoid muscle of the upper arm.

(2) The immunization schedule consists of 3 doses, administered at 0, 1, and 6 months. The dosage per administration for humans is 20μg/0.5ml.